Susanna High an Insider in bluebird bio, Inc. (BLUE) Sold 17,262 Shares; Big Lots, Inc. (BIG) Had 8 Bulls

Among 17 analysts covering Big Lots (NYSE:BIG), 8 have Buy rating, 1 Sell and 8 Hold. Therefore 47% are positive. Big Lots has $69.0 highest and $39 lowest target. $56.21’s average target is -5.78% below currents $59.66 stock price. Big Lots had 43 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer with “Buy” on Friday, August 25. Citigroup maintained it with “Buy” rating and $62 target in Monday, June 6 report. Wedbush maintained the stock with “Buy” rating in Wednesday, August 26 report. Oppenheimer maintained Big Lots, Inc. (NYSE:BIG) on Friday, May 26 with “Buy” rating. As per Wednesday, April 26, the company rating was upgraded by Raymond James. The stock has “Buy” rating by Citigroup on Thursday, September 1. The stock has “Buy” rating by KeyBanc Capital Markets on Tuesday, October 3. Wedbush maintained the shares of BIG in report on Tuesday, September 1 with “Buy” rating. The firm earned “Neutral” rating on Monday, December 7 by Piper Jaffray. The company was maintained on Monday, December 7 by M Partners. See Big Lots, Inc. (NYSE:BIG) latest ratings:

10/01/2018 Broker: Oppenheimer Rating: Hold Downgrade
03/12/2017 Broker: Barclays Capital Rating: Hold New Target: $54.0
05/12/2017 Broker: Citigroup Rating: Buy New Target: $69.0
04/12/2017 Broker: Telsey Advisory Group Rating: Market Perform Old Target: $56.00 New Target: $59.00 Maintain
01/12/2017 Broker: Raymond James Rating: Buy
01/12/2017 Broker: Piper Jaffray Rating: Hold New Target: $53.0 Maintain
03/10/2017 Broker: KeyBanc Capital Markets Rating: Buy New Target: $58.0 Maintain
29/09/2017 Broker: Piper Jaffray Rating: Hold New Target: $52.0 Maintain
25/09/2017 Broker: Morgan Stanley Rating: Overweight New Target: $58 Initiates Coverage On
30/08/2017 Broker: Loop Capital Markets Rating: Buy New Target: $64.0

In a legally required form that was filled with the Security Exchange Commission, we discovered that the Chief Operating Officer of Bluebird Bio Inc Susanna High, an insider in focus, made sale through a broker for 17,262 shares of the public company, having a market value of $3,381,792 USD using the average stock price of $195.9 USD. At the moment, Susanna High owns 11,250 shares which are around 0.02% of Bluebird Bio Inc’s total market capitalization.

Big Lots, Inc., through its subsidiaries, operates as a non-traditional, discount retailer in the United States. The company has market cap of $2.51 billion. The firm offers products under various merchandising categories, such as food category that includes beverage and grocery, candy and snacks, and specialty foods departments; consumables category, which comprises health and beauty, plastics, paper, chemical, and pet departments; soft home category that consists of home décor, frames, fashion bedding, utility bedding, bath, window, decorative textile, and area rugs departments; hard home category, including small appliances, table top, food preparation, stationery, greeting cards, and home maintenance departments; and furniture category consisting of upholstery, mattress, ready-to-assemble, and case goods departments. It has a 15.01 P/E ratio. It also provides merchandise under the seasonal category that includes lawn and garden, summer, Christmas, and other holiday departments; and electronics, toys, and accessories category, including electronics, jewelry, hosiery, toys, and infant accessories departments.

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.03, from 1 in 2017Q2. It improved, as 41 investors sold Big Lots, Inc. shares while 95 reduced holdings. 55 funds opened positions while 85 raised stakes. 51.55 million shares or 5.84% less from 54.74 million shares in 2017Q2 were reported. Livforsakringsbolaget Skandia Omsesidigt invested 0.11% of its portfolio in Big Lots, Inc. (NYSE:BIG). Bb&T reported 26,018 shares. Farmers & Merchants Inc invested in 0% or 139 shares. Citigroup Inc has 83,287 shares. Pub Employees Retirement Association Of Colorado invested in 8,360 shares. Winslow Asset Management Incorporated stated it has 1.41% in Big Lots, Inc. (NYSE:BIG). New York-based Euclidean Tech Limited Liability Corp has invested 1.5% in Big Lots, Inc. (NYSE:BIG). Hsbc Pcl accumulated 0% or 14,631 shares. Envestnet Asset Mgmt stated it has 0% of its portfolio in Big Lots, Inc. (NYSE:BIG). 7,107 are owned by Campbell Investment Adviser Lc. Northcoast Asset Mgmt Limited Liability Corp invested in 0.19% or 30,732 shares. Old Mutual (Uk) Ltd reported 1.12M shares stake. Verition Fund Limited Liability owns 6,123 shares or 0.03% of their US portfolio. Paloma Partners Mngmt invested in 16,030 shares or 0.01% of the stock. Boston Private Wealth Lc stated it has 0.02% of its portfolio in Big Lots, Inc. (NYSE:BIG).

Since August 4, 2017, it had 0 buys, and 7 insider sales for $7.24 million activity. Schlonsky Michael Allen also sold $124,896 worth of Big Lots, Inc. (NYSE:BIG) shares. Shares for $374,736 were sold by JOHNSON TIMOTHY A. Bachmann Lisa M had sold 40,000 shares worth $2.04M. The insider CAMPISI DAVID J sold 96,940 shares worth $5.14M. Another trade for 1,000 shares valued at $51,000 was sold by Robins Ronald A Jr. Berger Jeffrey Paul sold $348,000 worth of Big Lots, Inc. (NYSE:BIG) on Friday, January 5. 2,100 shares were sold by SOLT RUSSELL, worth $108,150 on Tuesday, August 8.

The stock decreased 1.84% or $1.12 during the last trading session, reaching $59.66. About 1.13M shares traded or 10.65% up from the average. Big Lots, Inc. (NYSE:BIG) has risen 10.65% since February 2, 2017 and is uptrending. It has underperformed by 6.05% the S&P500.

Among 25 analysts covering bluebird bio (NASDAQ:BLUE), 14 have Buy rating, 2 Sell and 9 Hold. Therefore 56% are positive. bluebird bio has $309.0 highest and $14 lowest target. $165.68’s average target is -19.28% below currents $205.25 stock price. bluebird bio had 81 analyst reports since August 11, 2015 according to SRatingsIntel. As per Friday, October 14, the company rating was maintained by Leerink Swann. Oppenheimer initiated the stock with “Outperform” rating in Tuesday, October 20 report. Wedbush maintained bluebird bio, Inc. (NASDAQ:BLUE) on Thursday, November 2 with “Buy” rating. Zacks downgraded bluebird bio, Inc. (NASDAQ:BLUE) on Tuesday, August 11 to “Buy” rating. The company was upgraded on Tuesday, June 6 by BMO Capital Markets. BTIG Research maintained the stock with “Hold” rating in Thursday, August 3 report. The firm has “Equal-Weight” rating by Morgan Stanley given on Monday, December 7. Cantor Fitzgerald initiated the stock with “Hold” rating in Friday, June 3 report. The rating was downgraded by Morgan Stanley to “Underweight” on Monday, October 2. The firm has “Buy” rating given on Friday, June 2 by Maxim Group.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $10.14 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.

Since August 3, 2017, it had 0 insider buys, and 27 insider sales for $48.70 million activity. Another trade for 7,000 shares valued at $1.52 million was made by Vachon Mark on Monday, December 11. 1,712 shares valued at $296,820 were sold by Gregory Philip D on Friday, January 5. 3,522 shares valued at $611,462 were sold by Davidson David on Friday, January 5. On Friday, January 5 the insider Leschly Nick sold $942,298. Another trade for 13,839 shares valued at $1.33 million was sold by MARAGANORE JOHN. 2,000 shares were sold by Schenkein David P, worth $230,145. Walsh Jeffrey T. sold $133,826 worth of bluebird bio, Inc. (NASDAQ:BLUE) on Monday, August 28.

Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on February, 28. They expect $-1.63 EPS, up 13.30% or $0.25 from last year’s $-1.88 per share. After $-1.73 actual EPS reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts -5.78% EPS growth.